NEW BRUNSWICK, N.J., April 18, 2018 /PRNewswire-USNewswire/ -- Visikol Inc., established with an investment from FoundationVenture Capital Group (FVCG), an affiliate of New Jersey Health Foundation (NJHF), has secured a new round of funding led by industry executives, announced James M. Golubieski, president of FVCG.
"This additional funding will allow the Visikol team to greatly accelerate its growth," said George F. Heinrich, M.D., vice chair and CEO of FVCG. "We are delighted that we could help the company get to this exciting point."
According to Viskiol CEO Michael Johnson, PhD, the financing round was completed with pharma services industry executives Brian Mulhall and Alan Weiss. Specific terms were not made public.
The new funding will be used to expand the company's commercial operations and to develop cutting edge bio-imaging services for drug discovery in the fields of advanced 3D in vitro assays, digital pathology and whole mount tissue imaging.
About Foundation Venture Capital Group
Foundation Venture Capital Group, an affiliate of New Jersey Health Foundation, invests in commercially viable new start-up companies developing health-related technology at major research universities in New Jersey with which they have affiliations. In addition to Visikol, FVCG portfolio companies currently include:
View original content:http://www.prnewswire.com/news-releases/visikol-receives-investment-to-advance-3screen-drug-discovery-300632330.html
SOURCE Foundation Venture Capital Group
Subscribe to our Free Newsletters!
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...
Birth Control Implant is a long-acting birth control contraceptive inserted into the arm. It is a ...
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...View All